E-LIB Suche - Ergebnisse für: Balar, A.V.

1

TROPHY-U-01, a phase II open-label study of sacituzumab gov..:

Loriot, Y. ; Petrylak, D.P. ; Rezazadeh Kalebasty, A....
Annals of Oncology. 35 (2024) 4 - p. 392-401 , 2024

Link: https://doi.org/10.1016/..

2

Efficacy and safety of pembrolizumab in metastatic urotheli..:

Balar, A.V. ; Castellano, D.E. ; Grivas, P....
Annals of Oncology. 34 (2023) 3 - p. 289-299 , 2023

Link: https://doi.org/10.1016/..

3

Updated follow-up from KEYNOTE-057: Phase 2 study of pembro..:

Boormans, J.L. ; De Wit, R. ; Kulkarni, G.S....
European Urology Open Science. 19 (2020) - p. e1173-e1174 , 2020

Link: https://doi.org/10.1016/..

4

Pembrolizumab for patients with high-risk non–muscle invasi..:

Boormans, J.L. ; Balar, A.V. ; De Wit, R....
European Urology Supplements. 18 (2019) 1 - p. e758-e759 , 2019

Link: https://doi.org/10.1016/..

5

Efficacy and Safety of Selective Vascular Endothelial Growt..:

Kang, S.K. ; Volodarskiy, A. ; Ohmann, E.L...
Clinical Oncology. 28 (2016) 5 - p. 334-341 , 2016

Link: https://doi.org/10.1016/..

6

A Phase 1/2 multicenter trial of DKN-01 as monotherapy or i..:

Wise, David R. ; Pachynski, Russell K. ; Denmeade, Samuel R....
Prostate Cancer and Prostatic Diseases. , 2024

Link: https://doi.org/10.1038/..

7

Pembrolizumab plus either epacadostat or placebo for cispla..:

Necchi, Andrea ; Van der Heijden, Michiel S. ; Trukhin, Dmytro...
BMC Cancer. 23 (2024) S1 - p. , 2024

Link: https://doi.org/10.1186/..

8

A plain language summary of the TROPHY-U-01 study: sacituzu..:

Loriot, Yohann ; Kalebasty, Arash Rezazadeh ; Fléchon, Aude...
Future Oncology. , 2024

Link: https://doi.org/10.2217/..

9

A unique case of protein-losing enteropathy in the setting ..:

Bernstein, Ezra ; Weinberger, James ; Baskin, Avi...
Current Problems in Cancer: Case Reports. 11 (2023) - p. 100252 , 2023

Link: https://doi.org/10.1016/..

10

Single‐cell analysis of localized prostate cancer patients ..:

Adorno Febles, Victor R. ; Hao, Yuan ; Ahsan, Aarif...
The Prostate. 83 (2023) 9 - p. 840-849 , 2023

Link: https://doi.org/10.1002/..

11

Bempegaldesleukin plus nivolumab in first-line renal cell c..:

Tannir, Nizar M ; Cho, Daniel C ; Diab, Adi...
Journal for ImmunoTherapy of Cancer. 10 (2022) 4 - p. e004419 , 2022

Link: https://doi.org/10.1136/..

12

Avelumab Plus Axitinib as First-Line Therapy for Advanced R..:

Larkin, James ; Oya, Mototsugu ; Martignoni, Marcella...
The Oncologist. 28 (2022) 4 - p. 333-340 , 2022

Link: https://doi.org/10.1093/..

13

Bempegaldesleukin plus Nivolumab in First-line Metastatic U..:

Siefker-Radtke, Arlene O. ; Cho, Daniel C. ; Diab, Adi...
European Urology. 82 (2022) 4 - p. 365-373 , 2022

Link: https://doi.org/10.1016/..

14

Society for Immunotherapy of Cancer (SITC) clinical practic..:

Galsky, Matthew D ; Balar, Arjun V ; Black, Peter C...
Journal for ImmunoTherapy of Cancer. 9 (2021) 7 - p. e002552 , 2021

Link: https://doi.org/10.1136/..

15

Corrigendum re "Fibroblast Growth Factor Receptor 3 Alterat..:

Teo, Min Yuen ; Mota, Jose Mauricio ; Whiting, Karissa A....
European Urology. 79 (2021) 5 - p. e158-e159 , 2021

Link: https://doi.org/10.1016/..